Clinical Trial Detail

NCT ID NCT03899792
Title A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors (LIBRETTO-121)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Loxo Oncology, Inc.
Indications

central nervous system cancer

Advanced Solid Tumor

Therapies

Selpercatinib

Age Groups: adult child

Additional content available in CKB BOOST